# Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Roy S. Herbst,Giuseppe Giaccone,Filippo de Marinis,Niels Reinmuth,A. Vergnenègre,Carlos H. Barrios,Masahiro Morise,Enriqueta Felip,Zoran Andrić,Sarayut Lucien Geater,Mustafa Özgüroğlu,Wei Zou,Alan Sandler,Ida Enquist,Kimberly M. Komatsubara,Yu Deng,Hiroshi Kuriki,Xiaohui Wen,Mark L. McCleland,Simonetta Mocci,Jacek Jassem,David R. Spigel |
| Citations | 1,714 |
| DOI | 10.1056/nejmoa1917346 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1917346?articleTools=true |
| OpenAlex ID | https://openalex.org/W3091399767 |
| PMID | 32997907 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Enriqueta Felip](https://scholariq.org/researchers/enriqueta-felip/)
- [David R. Spigel](https://scholariq.org/researchers/david-r-spigel/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.